High-Throughput Screening/High-Content Screening
As a partner of national pharmaceutical companies and research institutions, Creative Biolabs provides tailor-made services and assays for the early stages of the nucleic drug development process and is equipped with modern advances in high-speed computers, robotics, plate reader detection which ensure the highest throughput while minimizing sample consumption and costs.
What is high-throughput screening/high-content screening?
High-throughput screening (HTS) allow to rapidly interrogate thousands to hundreds of thousands of small molecules for a specific biological target in a variety of in vitro and cell-based assays. Although the results of high-throughput drug screening are accurate and easy to evaluate, their detection models are based on the single drug acting on the target molecule and cannot fully reflect the biological activity characteristics of the sample being screened. Cell-based High-Content Screening (HCS) technology enables the simultaneous detection of multiple targets and multiple parameters of a compound, enabling a comprehensive evaluation of the drug ability of a compound at the cellular level, which is playing an increasingly important role in the development of new drugs.
High-throughput screening/high-content screening in nucleic acid drugs discovery
High-throughput screening is an efficient method for drug screening, and a large amount of valuable drug information can be obtained in one experiment. It combines sophisticated automation systems, including dedicated software, multiple operating systems, computers, and robotic grippers. Those robotic grippers are used to process microplates automatically at each step of a prescribed assay. Analytical microplates contain a large number of wells (384, 1,536, or 3,456 wells per plate), and samples from spare plates in the compound library are applied to each well. Creative Biolabs can set up high-throughput screening methods according to users’ needs to quickly screen safe and effective “hits” or nucleic acid drug carriers.
Some key factors and our systems during High-throughput screening/high-content screening process
Successful high-throughput screening/high content screening relies on many factors including; assay design, target selection, software and hardware design, selection of the library, data management and effective statistical analysis. Creative Biolabs is equipped with the new reference multi-mode microplate PHERAstar® FSX reader, microplate cytometer TTP Acumen® eX3 and the robotic workstation for HTS applications.
- PHERAstar® FSX reader is the most sensitive and versatile microplate reader on the market, capable of performing all advanced non-isotopic detection technologies, and has unmatched sensitivity in fluorescence intensity and fluorescence polarization detection modes. In addition, PHERAstar® FSX provides ultra-high dynamic range for high-performance chemiluminescence, enabling greater flexibility and higher measurement accuracy.
- TTP Acumen® eX3 can comprehensively analyze the state, change and overall trend of the cells, and obtain analysis results with high-content and reliability. It has good applications in many aspects such as apoptosis, cell cycle, cytotoxicity, receptor protein translocation, and protein interaction.
Our platform answers your high-throughput screening/high-content screening needs
- Accurate planning and arrangement to provide consistent well-to-well treatment regardless of your daily throughput requirements.
- Simplified data management software that makes it easy to run and extract reports for analysis without the help of other IT department.
- The flexibility of the system allows you to do what you need, whether for simple measurements or complex screening.
References
- Xia X, Wong ST. Concise review: a high-content screening approach to stem cell research and drug discovery. Stem Cells. 2012;30(9):1800-1807. doi:10.1002/stem.1168.
- Damm-Ganamet KL, Arora N, et al. Accelerating Lead Identification by High Throughput Virtual Screening: Prospective Case Studies from the Pharmaceutical Industry. J Chem Inf Model. 2019;59(5):2046-2062. doi:10.1021/acs.jcim.8b00941
- Xu L, Zhang Y, et al. Discovery of novel inhibitors targeting the macrophage migration inhibitory factor via structure-based virtual screening and bioassays. J Med Chem. 2014;57(9):3737-3745. doi:10.1021/jm401908w
*For Research Use Only. Not for use in diagnostic procedures.
